About Methionine aminopeptidase 1D, mitochondrial
Methionine aminopeptidase 1D, mitochondrial (METAP1D) is a protein
from Homo sapiens identified by UniProt accession
Q6UB28, 335 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Methionine aminopeptidase 1D, mitochondrial |
|---|
| UniProt accession | Q6UB28 |
|---|
| Gene | METAP1D |
|---|
| Organism | Homo sapiens |
|---|
| Length | 335 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (34)
Diseases linked to this target (Open Targets).
- reaction time measurement · score 0.26
- body height · score 0.25
- self reported educational attainment · score 0.23
- Myopia · score 0.16
- Abnormality of refraction · score 0.14
- refractive error · score 0.13
- Hypermetropia · score 0.13
- acute myeloid leukemia · score 0.09
- age at onset · score 0.08
- body mass index · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6UB28-F1 | alphafold | PREDICTED | 88.73 | — |
Amino-acid sequence (335 residues)
MAAPSGVHLL VRRGSHRIFS SPLNHIYLHK QSSSQQRRNF FFRRQRDISH SIVLPAAVSS AHPVPKHIKK PDYVTTGIVP DWGDSIEVKN EDQIQGLHQA CQLARHVLLL AGKSLKVDMT TEEIDALVHR EIISHNAYPS PLGYGGFPKS VCTSVNNVLC HGIPDSRPLQ DGDIINIDVT VYYNGYHGDT SETFLVGNVD ECGKKLVEVA RRCRDEAIAA CRAGAPFSVI GNTISHITHQ NGFQVCPHFV GHGIGSYFHG HPEIWHHAND SDLPMEEGMA FTIEPIITEG SPEFKVLEDA WTVVSLDNQR SAQFEHTVLI TSRGAQILTK LPHEA
Explore Methionine aminopeptidase 1D, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets